

Day One: Wrap-up & Closing Remarks

Hocine Abid, MD, MBA

National Manager, Clinical Compliance & Border Operations Regulatory Operations & Enforcement Branch | Health Canada

A Joint US-FDA | MHRA-UK | Health Canada Good Clinical Practice & Pharmacovigilance Compliance Workshop February 13, 2024



Medicines & Healthcare products Regulatory Agency



Health Canada Santé Canada

Overview


- Harmonization
- Digital Health Technology
- Innovations in Design
- Data Governance

Harmonization

- Updates to ICH E6, include
 - New Data Governance section
 - Appendices: IBs, protocol and amendments and essential records.
 - Deviation management (emphasis on impact to participant safety and data integrity)
 - Sponsor responsibility inclusive trial design


Harmonization

- Glossary terms/themes, to name a few...
 - Quality by design, risk proportionate, inclusive
 - Feasibility, fit-for-purpose
 - Annex 2
 - Decentralized elements
 - Pragmatic elements
 - Real world data sources




Innovations in design

- Decentralized elements offer flexibility
- Leveraging technology where appropriate
- Importance for sponsor oversight being maintained
- Proper planning is essential and includes the engagement of regulators



Data Governance

- Identify the critical-to-quality factors though each stage of the data life cycle
- Communication with all study personnel is key, and consider their input
- Risk-proportionate management of computerized systems and data governance processes
- Importance of validation are systems purpose-fit?



Looking forward

- Sponsor Oversight
- Clinical Trials Post-Pandemic
- The Future of GCP Inspections
- Agency Updates
- Collaboration Between Agencies and Future Expectations





Medicines & Healthcare products Regulatory Agency



Santé Canada